Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study
Pediatric Blood & Cancer · 17.11.2026
DOI: 10.1002/1545-5017.70820 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 17.11.2026. Verfasst von Clara Rigaud Vanderkelen und 16 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Neurofibromatosis type 1 (NF‐1) frequently leads to inoperable, symptomatic plexiform neurofibromas (PNs) with limited therapeutic options. This study evaluates the real‐world activity and safety of the MEK inhibitor trametinib in pediatric NF‐1 patients with inoperable PNs in France.
Methods
We analyzed pediatric patients enrolled in the SACHA‐France study (NCT04477681) who received trametinib for inoperable PNs between 01/2020 and 01/2026. Antitumor activity was evaluated by treating physicians using response evaluation criteria in solid tumors (RECIST) 1.1 criteria. Adverse events (AEs) were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Clinical benefit data were collected retrospectively.
Results
Twenty‐three patients (median age: 6 years [range: 0–17]) were included. Clinical benefit occurred in 87% (20/23), mainly through pain reduction (86% of symptomatic patients, 12/14). RECIST assessment showed partial response in 4% (1/23), stable disease in 87% (20/23), and progression in 9% (2/23). AEs occurred in 96% of patients, predominantly cutaneous (96%) and Grade 1–2. Four Grade 3 AEs were reported (osteitis, paronychia [ n = 2], elevated creatine kinase), prompting discontinuation in 2 cases. Median treatment duration was 33 months [range: 1–58]. Treatment was discontinued in seven patients for prolonged stable disease, four for disease progression (two clinical, two radiological), two for severe AEs, and one for poor adherence. Nine patients remained on treatment at cutoff.
Conclusion
Trametinib provided notable clinical benefit and disease stabilization in pediatric NF‐1‐associated PNs, despite limited RECIST‐defined tumor shrinkage. The safety profile was manageable and consistent with known data. Comparative studies with other MEK inhibitors are warranted to optimize treatment strategies.
Zitieren
APA
Vanderkelen, C. R., Aerts, I., Sevrin, F., Ndounga‐Diakou, L. A., Abbou, S., Reguerre, Y., Entz‐Werle, N., Khanfar, C., Leblond, P., Faure‐Conter, C., Carausu, L., Ducassou, S., Freycon, C., Pagnier, A., Vassal, G., Berlanga, P., & Andre, N. (2026). Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70820
Vancouver
Vanderkelen CR, Aerts I, Sevrin F, Ndounga‐Diakou LA, Abbou S, Reguerre Y, et al. Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70820
BibTeX
@article{Vanderkelen2026,
author = {Vanderkelen, Clara Rigaud and Aerts, Isabelle and Sevrin, François and Ndounga‐Diakou, Lee Aymar and Abbou, Samuel and Reguerre, Yves and Entz‐Werle, Natacha and Khanfar, Camille and Leblond, Pierre and Faure‐Conter, Cécile and Carausu, Liana and Ducassou, Stéphane and Freycon, Claire and Pagnier, Anne and Vassal, Gilles and Berlanga, Pablo and Andre, Nicolas},
title = {Trametinib in Neurofibromatosis Type 1‐Associated Plexiform Neurofibroma—Real‐World Data From the SACHA‐France Study},
journal = {Pediatric Blood & Cancer},
year = {2026},
doi = {10.1002/1545-5017.70820}
}
EUVIMED